Regeneration of cochlear outer hair cells by ectopic combined overexpression of Atoh1 and Ikzf2 and its application
By combining the overexpression of Ikzf2 and Atoh1 proteins in cochlear support cells, the regeneration of extracochlear hair cells is achieved using adeno-associated viral vectors, solving the problems of low regeneration efficiency and insufficient functionality in the prior art, successfully restoring auditory function, providing A new gene therapy method has been developed.
Patent Information
- Application Number
- CN202110018325.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-01-07
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-01-07
AI Technical Summary
In the prior art, in the treatment of hearing damage, new cells with low regeneration efficiency of cochlea hair cells and regenerated are ineffective and difficult to effectively restore hearing.
By combining the overexpression of Ikzf2 and Atoh1 proteins in cochlear support cells, it is converted into functional extrahair cell-like cells, and the coding sequences of Ikzf2 and Atoh1 are introduced into cochlear support cells using adeno-associated viral vectors to promote the regeneration of extrahair cells of cochlear hair.
The efficient regeneration of extracochlear hair cells is achieved, the production of similar functional OHC-like cells, and the recovery or maintenance of auditory functions is provided, providing a new gene therapy method for the treatment of hearing impairment.
Smart Images

Figure BDA0002887806870000131 
Figure HDA0002887806880000011 
Figure HDA0002887806880000021
Abstract
Description
Technical Field
[0001] The invention relates to the fields of biological preparations and biotechnology, and in particular to Atoh1 and Ikzf2 combined overexpression to regenerate cochlear outer hair cells and applications thereof. Background Art
[0002] Mammalian cochlear outer hair cells (OHCs) are essential for hearing, but OHCs are very sensitive to various ototoxic drugs, noise, and aging. OHC degeneration or damage leads to severe hearing impairment. In previous in vivo studies, although there have been precedents for treating hearing loss through OHC regeneration, its efficiency is low and the regenerated new OHCs are usually non-functional.
[0003] Therefore, there is an urgent need in this research field to develop a method for regenerating OHC in the case of OHC degeneration or damage in vivo to treat hearing loss. Summary of the invention
[0004] The purpose of the present invention is to provide a gene therapy method and therapeutic drug that can effectively treat hearing loss.
[0005] In a first aspect, the present invention provides a use of a combination of active ingredients for preparing a preparation or a medicament for: (i) regenerating cochlear outer hair cells; and / or (ii) treating or preventing hearing loss;
[0006] Wherein, the active ingredient combination comprises:
[0007] (a) Ikzf2 protein, its coding sequence, or its promoter, or a combination thereof; and
[0008] (b) Atoh1 protein, its coding sequence, or its promoter, or a combination thereof.
[0009] In another preferred example, the Ikzf2 protein has an amino acid sequence as shown in SEQ ID NO.:1.
[0010] In another preferred example, the Atoh1 protein has an amino acid sequence as shown in SEQ ID NO.:2.
[0011] In another preferred embodiment, the hearing loss is hearing loss associated with degeneration and / or damage of cochlear outer hair cells (OHC).
[0012] In another preferred embodiment, the cochlear outer hair cells are cochlear outer hair cells of humans or non-human mammals.
[0013] The second aspect of the present invention provides a combination of active ingredients that can be used to regenerate cochlear outer hair cells, comprising:
[0014] (a) Ikzf2 protein, its coding sequence, or its promoter, or a combination thereof; and
[0015] (b) Atoh1 protein, its coding sequence, or its promoter, or a combination thereof.
[0016] In another preferred example, the Ikzf2 protein has an amino acid sequence as shown in SEQ ID NO.:1.
[0017] In another preferred example, the Atoh1 protein has an amino acid sequence as shown in SEQ ID NO.:2.
[0018] The third aspect of the present invention provides an expression vector, wherein the expression vector comprises:
[0019] (Z1) a first expression vector, which contains a first expression cassette for expressing the Ikzf2 protein;
[0020] (Z1) a second expression vector, wherein the second expression vector contains a second expression cassette for expressing the Atoh1 protein;
[0021] Wherein, the first expression vector and the second expression vector are the same vector or different vectors.
[0022] In another preferred embodiment, the expression vector comprises a viral vector.
[0023] In another preferred embodiment, the expression vector is selected from the following group: plasmid, viral vector.
[0024] In another preferred embodiment, the expression vector is selected from the following group: a lentiviral vector, an adenoviral vector, an adeno-associated viral vector (AAV), or a combination thereof.
[0025] In another preferred embodiment, the expression vector is an adeno-associated virus AAV vector.
[0026] In another preferred embodiment, the AAV vector is AAV7m8, AAV-anc80, or AAV-ie.
[0027] In another preferred example, the expression vector is used to express Ikzf2 protein and / or Atoh1 protein.
[0028] In another preferred example, the expression vector contains a nucleotide sequence encoding Ikzf2 protein and / or Atoh1 protein.
[0029] In another preferred example, the nucleotide sequence encoding the Ikzf2 protein is shown as SEQ ID NO.:3.
[0030] In another preferred example, the nucleotide sequence encoding the Atoh1 protein is shown as SEQ ID NO.:4.
[0031] In another preferred embodiment, the first expression cassette has a structure of Formula I from the 5' end to the 3' end:
[0032] Z0-Z1-Z2 (I)
[0033] In the formula,
[0034] Each "-" is independently a chemical bond or a nucleotide connection sequence;
[0035] Z0 is none or 5'UTR sequence;
[0036] Z1 is a nucleotide sequence encoding Ikzf2 protein; and
[0037] Z2 is none or 3'UTR sequence.
[0038] In another preferred embodiment, the second expression cassette has a structure of Formula II from the 5' end to the 3' end:
[0039] Z0'-Z1'-Z2' (II)
[0040] In the formula,
[0041] Each "-" is independently a chemical bond or a nucleotide connection sequence;
[0042] Z0' is none or 5'UTR sequence;
[0043] Z1' is a nucleotide sequence encoding Atoh1 protein; and
[0044] Z2' is none or 3'UTR sequence.
[0045] In another preferred embodiment, the length of each nucleotide linker sequence is 1-30 nt, preferably 1-15 nt, and more preferably 3-6 nt.
[0046] In another preferred embodiment, the nucleotide linker sequence is derived from a nucleotide linker sequence formed by restriction endonuclease cleavage.
[0047] The fourth aspect of the present invention provides a host cell, wherein the host cell contains the expression vector described in the third aspect of the present invention.
[0048] In another preferred embodiment, the host cell is a mammalian cell, and the mammal includes human and non-human mammals.
[0049] In another preferred embodiment, the host cell is selected from the following group: cochlear supporting cells (SC), including columnar cells (PC), Deiters cells (DC) or a combination thereof; preferably, the host cell is a columnar cell (PC).
[0050] The fifth aspect of the present invention provides a pharmaceutical preparation, which contains (a) the active ingredient combination as described in the second aspect of the present invention, or the carrier as described in the third aspect of the present invention, or the cell as described in the fourth aspect of the present invention, and (b) a pharmaceutically acceptable carrier or excipient.
[0051] In another preferred embodiment, the dosage form of the pharmaceutical preparation is selected from the following group: a lyophilized preparation, a liquid preparation, or a combination thereof.
[0052] In another preferred embodiment, the vector is selected from the following group: a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a combination thereof; preferably, the vector is an AAV vector; more preferably, it is AAV7m8, AAV-anc80, or AAV-ie.
[0053] In another preferred embodiment, the content of the carrier in the pharmaceutical preparation is 1x10 12 -1x10 14 Viruses / ml, preferably 1x10 13 viruses / ml.
[0054] In another preferred embodiment, the therapeutically effective amount of the pharmaceutical preparation is 1x10 9 -1x10 11 viruses, preferably 1x10 10 A virus.
[0055] In another preferred embodiment, the pharmaceutical preparation is used to treat or prevent hearing loss, preferably to treat degeneration and / or damage of cochlear outer hair cells.
[0056] The sixth aspect of the present invention provides a use of the active ingredient combination as described in the second aspect of the present invention, the expression vector as described in the third aspect of the present invention, the host cell as described in the fourth aspect of the present invention, or the pharmaceutical preparation as described in the fifth aspect of the present invention in the treatment or prevention of hearing impairment.
[0057] In another preferred embodiment, the hearing loss is hearing loss associated with degeneration and / or damage of cochlear outer hair cells (OHC).
[0058] The seventh aspect of the present invention provides a method for treating or preventing hearing loss, which comprises administering the pharmaceutical preparation described in the fifth aspect of the present invention to a subject in need thereof.
[0059] In another preferred embodiment, the hearing loss is hearing loss associated with degeneration and / or damage of cochlear outer hair cells.
[0060] In another preferred embodiment, the method is a method for reducing degeneration and / or damage of cochlear outer hair cells in a patient suffering from or at risk of developing hearing loss.
[0061] In another preferred embodiment, the subject in need includes human and non-human mammals.
[0062] In another preferred embodiment, the subject in need suffers from hearing loss associated with degeneration and / or damage of cochlear outer hair cells.
[0063] In another preferred embodiment, the method comprises directly administering the vector of the present invention to the ear of a subject in need thereof.
[0064] In another preferred embodiment, the method comprises directly implanting the host cell of the present invention into the cochlea of a subject in need thereof.
[0065] In another preferred embodiment, the method can regenerate cochlear outer hair cells in a subject in need thereof who suffers from hearing loss associated with cochlear outer hair cell degeneration and / or damage.
[0066] In another preferred embodiment, the method results in substantial restoration or maintenance of hearing function in the treated ear.
[0067] The eighth aspect of the present invention provides a method for regenerating cochlear outer hair cells, comprising transducing the active ingredient combination described in the second aspect of the present invention, or the expression vector described in the third aspect of the present invention, into cochlear supporting cells.
[0068] In another preferred embodiment, the cochlear supporting cells are columnar cells (PC), including Deiters cells (DC) or a combination thereof.
[0069] The ninth aspect of the present invention provides a use of an active ingredient for preparing a preparation or a medicine, wherein the preparation or the medicine is used for: (i) promoting the regeneration of cochlear outer hair cells; and / or (ii) assisting in the treatment or prevention of hearing loss;
[0070] Wherein, the active ingredients include: Ikzf2 protein, its coding sequence, or its promoter, or a combination thereof.
[0071] In another preferred example, the Ikzf2 protein has an amino acid sequence as shown in SEQ ID NO.:1.
[0072] In another preferred embodiment, the hearing loss is hearing loss associated with degeneration and / or damage of cochlear outer hair cells (OHC).
[0073] In another preferred embodiment, the cochlear outer hair cells are cochlear outer hair cells of humans or non-human mammals.
[0074] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1 :After ectopic overexpression of Ikzf2 in inner hair cells, inner hair cells begin to express Prestin. (A) Use a diagram to explain how to initiate ectopic expression of Ikzf2 in hair cells. Tdtomato and Ikzf2 (HA tag) are expressed in association. Atoh1-CreER+ serves as an effective activation tool for early hair cells. (BC”') Prestin, vGlut3 and Tdtomato were simultaneously stained in the control group Atoh1-CreER+ (BB”') and the experimental group Atoh1-CreER+; Rosa26-CAG-LSL-Ikzf2 / + (CC”') at P42. Among them, Prestin is only expressed in wild-type outer hair cells (BB”'). In (CC'), arrows indicate inner hair cells that co-express Tdtomato / vGlut3 / Prestin, and asterisks indicate inner hair cells that do not express Prestin in the experimental group. (D) Quantitative analysis of Prestin-positive inner hair cells. **p<0.01. (EF) Co-staining of HA / Tdtomato in the control group (E) and experimental group (F) at P42. Scale bars: 20 μm.
[0076] Figure 2: Overexpression of Atoh1 and Ikzf2 in PCs and DCs of adult mice simultaneously generates a small number of OHC-like cells. In four mice, TMX was given at P30 and P31 and analyzed at P60, HA, Tdtomato, and Prestin were stained simultaneously. (AA”’) In Fgfr3-iCreER+;Ai9 / +(Fgfr3-Ai9) mice, all Tdtomato-positive cells are supporting cells SC: PCs and DCs. The inset in (A’) shows the supporting cell layer. The arrow marks a Prestin+ / Tdtomato- outer hair cell. (BB”’) In Fgfr3-iCreER+;CAG-LSL-Atoh1+(Fgfr3-Atoh1) mice, there is no Tdtomato signal and no Prestin+ / HA+ double positive signal. The inset in (B) shows the supporting cell layer. (CD"') In Fgfr3-iCreER+; Rosa26-CAG-LSL-Ikzf2 / +(Fgfr3-Ikzf2) mice, (CC"') shows the hair cell layer and (DD"') shows the supporting cell layer. Arrows indicate HA+ / Tdtomato+ but Pestin- cells in both layers, while the original Prestin+ outer hair cells are abnormal. (EF"') Hair cell (EE"') and supporting cell layers (FF"') in Fgfr3-iCreER+; CAG-LSL-Atoh1+; Rosa26-CAG-LSL-Ikzf2 / +(Fgfr3-Atoh1-Ikzf2) mice. According to the position and morphology, the arrows in (EE') mark the HA+ / Tdtomato+ / Prestin+ OHC-like cells transformed from adult DCs, and the arrows in (FF') show the HA+ / Tdtomato+ / Prestin+ OHC-like cells transformed from adult PCs. The arrows mark the Prestin+ / Tdtomato- in situ outer hair cells falling into the supporting cell layer. Obviously, the Prestin signal in OHC-like cells is weaker than that in situ outer hair cells. (G) Quantitative analysis of OHC-like cells in Fgfr3-Atoh1-Ikzf2 mice. Data were statistically analyzed using Mean±SEM (n=3). (H) Summary of the reprogramming results of the three models. Scale bars: 20μm.
[0077] Figure 3: Specific damage to outer hair cells by genetic and pharmacological methods. (A-B') Prestin-P2A-DTR / + mice were given diphtheria toxin (DT) (A-A', control without DT) or (B-B', experimental group with DT) at P36 and analyzed at P42. Samples were stained with Prestin and vGlut3 at the same time. (A') and (B') show the white box areas in (A) and (B), respectively. (The arrow in B') shows that after 6 days of administration, most outer hair cells died rapidly, leaving a large amount of green residual debris, with only a small number of remaining outer hair cells (arrow in B'). (C) Auditory brainstem responses of Prestin-P2A-DTR / + mice, control (blue line, without DT) and experimental group (red line, with DT). (D) The ratio of outer hair cells to inner hair cells in the experimental group (red line) and the control group (blue line). Scale bars: 200μm (B), 20μm (B').
[0078] Figure 4 : Damage to outer hair cells in situ can promote the reprogramming efficiency of overexpressing Atoh1 and Ikzf2 in adult supporting cells. (A) For different cell models, TMX was given at P30 and 31, DT was given at P36, and analysis was performed at P60. (B) A cartoon diagram explains that at the cellular level, after overexpression of Atoh1 and Ikzf2 in adult PCs and DCs, Tdtomato can permanently mark supporting cells. (CG”’) HA, Tdtomato and mitochondrial expression were simultaneously expressed in 4 different mouse models: 1) Prestin-DTR / + (C and D), 2) Fgfr3-iCreER+; CAG-LSL-Atoh1+; Prestin-DTR / + (Fgfr3-Atoh1-DTR) (E), 3) Fgfr3-iCreER+; Rosa26-CAG-LSL-Ikzf2 / +; Prestin-DTR / + (Fgfr3-Ikzf2-DTR) (F), and 4) Fgfr3-iCreER+; CAG-LSL-Atoh1+; Rosa26-CAG-LSL-Ikzf2 / +; Prestin-DTR / + (Fgfr3-Atoh1-Ikzf2-DTR) (GG””) Prestin. At P60, compared with intact hair cells in Prestin-DTR / + mice without DT treatment (C), only a few hair cells remained in DT-treated Prestin-DTR / + mice (arrows in D). Figure 2), the debris of dead outer hair cells disappeared. Although OHC-like cells were not generated in the first three mouse models, Tdtomato+ / HA+ / Prestin+OHC-like cells were generated in the Fgfr3-Atoh1-Ikzf2-DTR mouse model (arrows in GG”). (H) Quantitative analysis of the number of OHC-like cells in Fgfr3-Atoh1-Ikzf2-DTR mice. (I) Comparison of the number of OHC-like cells in Fgfr3-Atoh1-Ikzf2-DTR and Fgfr3-Atoh1-Ikzf2 (without destruction of in situ outer hair cells) mouse models. Scale bars: 20μm.
[0079] Figure 5 : Results of scanning electron microscopy (SEM) analysis of OHC-like cells. (A-A') In Prestin-DTR / + mice without DT treatment, outer hair cells exhibited V- or W-shaped ciliary bundles. (A') shows an enlarged view of the black box area in (A). (B) In Prestin-DTR / + mice given DT at P36, the black asterisk indicates a missing inner hair cell. (C) In the Fgfr3-iCreER+; CAG-LSL-Atoh1+; Rosa26-CAG-LSL-Ikzf2 / +; Prestin-DTR / + (Fgfr3-Atoh1-Ikzf2-DTR) model, irregular ciliary bundles were observed. They should be derived from OHC-like cells. (C') The black box shows an enlarged view of (C). Ciliary bundles in the inset of C were rarely observed, and the black asterisk indicates a missing inner hair cell. Scale bars: 5μm (A, B, C), 1μm (C') and 500nm (A').
[0080] Figure 6: OHC-like cells are similar to wild-type outer hair cells at P1. (A) Hand-picked Tdtomato+ cells in three mouse models and cartoon images of single-cell sequencing. (BC”’) Myo7a, Prestin and Tdtomato were stained in cochlear samples of control (B) and Fgfr3-Atoh1-Ikzf2-DTR (C) mice at P60. Arrows indicate Tdtomato+ / Myo7a+ / Prestin+ OHC-like cells, and arrowheads indicate Tdtomato+ / Myo7a- / Prestin- cells. Asterisks mark Tdtomato+ / Myo7a+ / Prestin- cells (C”-C”’). (D) Sequencing of five cells (E) Pearson correlation analysis of the five different cell types in (D). (FG) UMAP analysis of cell types other than supporting cells that cannot transform into hair cells in (DE) (wild-type outer hair cells: E16, P1, P7, P30, and supporting cells at P60, reprogrammed hair cells). DETAILED DESCRIPTION
[0081] After extensive and in-depth research, the inventors have successfully converted adult cochlear SCs (mainly columnar cells and Deiters cells) into Prestin+OHC-like cells for the first time by ectopically expressing Atoh1 and Ikzf2, two key transcription factors (TFs) necessary for OHC development. The transformed OHC-like cells upregulated hundreds of OHC genes and downregulated their original SC genes. By comparing single-cell transcriptomes, it was found that OHC-like cells were very similar to wild-type OHCs. In summary, the present invention has established a new and effective method to regenerate OHCs in damaged cochleae, which has the potential to regenerate OHCs clinically.
[0082] On this basis, the present invention has been completed.
[0083] the term
[0084] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.
[0085] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0086] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0087] As used herein, the term "subject", "subject in need" refers to any mammal or non-mammal. Mammals include, but are not limited to, humans, vertebrates such as rodents, non-human primates, cows, horses, dogs, cats, pigs, sheep, goats.
[0088] As used herein, the terms "hearing loss," "hearing disorder," and "hearing impairment" refer to abnormal hearing function due to degeneration and / or damage of the cochlear outer hair cells.
[0089] Cochlear outer hair cells (OHC)
[0090] As used herein, the terms "cochlear outer hair cell," "OHC," and "outer hair cell" have the same meaning and can be used interchangeably herein.
[0091] Mammalian sound receptor hair cells (HCs) are distributed throughout the auditory epithelium, known as the organ of Corti (OC). Proximally to the HCs are several subtypes of supporting cells (SCs), which, from medial to lateral, are columnar cells (PCs) and Deiters cells (DCs). There are two subtypes of auditory HCs: inner hair cells (IHCs) and outer hair cells (OHCs). OHCs specifically express a unique motor protein, Prestin, encoded by Slc26a5. Prestin-mediated electrical movement makes OHCs sound amplifiers, which is essential for sound detection. Prestin- / - mice suffer from severe hearing loss. Unlike OHCs, IHCs are primary sensory cells that are innervated by spiral ganglion neurons (SGNs) in the cochlea. IHC specificity is determined by vGlut3, encoded by Slc17a8, which is required for the conversion of sound information from IHCs to SGNs. vGlut3- / - mice are completely deaf. IHCs and OHCs share the same Atoh1+ progenitors.
[0092] Ikzf2 protein
[0093] Ikzf2 (IKAROS Family Zinc Finger 2) is a zinc finger protein, and another common name is Helios. For more information, see:
[0094] https: / / www.ncbi.nlm.nih.gov / gene / 22807 (human);
[0095] https: / / www.ncbi.nlm.nih.gov / gene / 22779 (mouse).
[0096] In the present invention, the amino acid sequence of the Ikzf2 protein is shown in SEQ ID NO.: 1 (human) and SEQ ID NO.: 5 (mouse); the nucleotide coding sequence is shown in SEQ ID NO.: 3 (human) and SEQ ID NO.: 7 (mouse).
[0097] Ikzf2 is essentially a transcription factor distributed in the cell nucleus, and its main function is to activate the expression of specific genes. In the mouse cochlea, Ikzf2 begins to be expressed after birth, and is specifically expressed in the cochlear outer hair cells (OHC). Other cells of the cochlea do not express it or express it at very low levels. Mouse Ikzf2 mutant mice show abnormal development of cochlear outer hair cells and hearing impairment.
[0098] Atoh1 protein
[0099] Atoh1 (atonal bHLH transcription factor 1) is a nuclear transcription factor of the bHLH family. Another common name is math1. For more information, see:
[0100] https: / / www.ncbi.nlm.nih.gov / gene / 474 (human);
[0101] https: / / www.ncbi.nlm.nih.gov / gene / 11921 (mouse).
[0102] In the present invention, the amino acid sequence of the Atoh1 protein is shown in SEQ ID NO.: 2 (human) and SEQ ID NO.: 6 (mouse); the nucleotide coding sequence is shown in SEQ ID NO.: 4 (human) and SEQ ID NO.: 8 (mouse).
[0103] Atoh1 is essentially a transcription factor distributed in the cell nucleus, and its main function is to activate the expression of specific genes. In the mouse cochlea, Atoh1 begins to be expressed in the cochlea in the middle embryonic stage, and its main function is to allow the progenitor cells of the cochlear auditory epithelium to develop into hair cells. Mice lacking Atoh1 cannot produce hair cells.
[0104] Adeno-associated virus
[0105] Adeno-associated virus (AAV), also known as adeno-associated virus, belongs to the genus Dependinovirus of the family Parvoviridae. It is the simplest type of single-stranded DNA defective virus discovered so far, and requires a helper virus (usually adenovirus) to participate in replication. It encodes the cap and rep genes in the inverted repeat sequences (ITR) at both ends. ITR plays a decisive role in the replication and packaging of the virus. The cap gene encodes the viral capsid protein, and the rep gene is involved in the replication and integration of the virus. AAV can infect a variety of cells.
[0106] Recombinant adeno-associated virus vector (rAAV) is derived from non-pathogenic wild-type adeno-associated virus. Due to its good safety, wide range of host cells (dividing and non-dividing cells), low immunogenicity, and long-term expression of foreign genes in vivo, it is regarded as one of the most promising gene transfer vectors and has been widely used in gene therapy and vaccine research worldwide. After more than 10 years of research, the biological characteristics of recombinant adeno-associated virus have been deeply understood, especially its application effects in various cells, tissues and in vivo experiments have been accumulated. In medical research, rAAV has been used in the study of gene therapy for a variety of diseases (including in vivo and in vitro experiments); at the same time, as a characteristic gene transfer vector, it is also widely used in gene function research, construction of disease models, preparation of gene knockout mice, etc.
[0107] Expression vectors and host cells
[0108] The present invention provides an expression vector for expressing Ikzf2 protein and Atoh1 protein, which contains the coding sequences of the Ikzf2 protein and Atoh1 protein of the present invention.
[0109] Given the sequence information, a skilled artisan can use available cloning techniques to generate nucleic acid sequences or vectors suitable for transduction into cells.
[0110] Preferably, the nucleic acid sequence encoding Ikzf2 protein and Atoh1 protein is provided as a vector, preferably as an expression vector. Preferably, it can be provided as a gene therapy vector preferably suitable for transduction and expression in target cells (e.g., cochlear supporting cells). The vector can be viral or non-viral (e.g., plasmid). Viral vectors include those derived from the following: adenovirus, adeno-associated virus (AAV) including mutant forms, retrovirus, lentivirus, herpes virus, vaccinia virus, MMLV, GaLV, simian immunodeficiency virus (SIV), HIV, poxvirus and SV40. Preferably, the viral vector is replication defective, or can be replication deficient, capable of replication or conditional replication. The viral vector can generally maintain an extrachromosomal state without integrating into the genome of the target cell. The preferred viral vector for introducing the nucleic acid sequence encoding Ikzf2 protein and Atoh1 protein into the target cell is an AAV vector. Selective targeting can be achieved using specific AAV serotypes (AAV serotype 2 to AAV serotype 12) or modified versions of any of these serotypes. In a preferred embodiment of the present invention, the AAV vector is preferably AAV7m8, AAV-anc80, or AAV-ie.
[0111] The viral vector can be modified to delete any non-essential sequence. For example, in AAV, the virus can be modified to delete all or part of the IX gene, Ela and / or Elb gene. For wild-type AAV, without the presence of a helper virus such as adenovirus, replication is very inefficient. For recombinant adeno-associated viruses, preferably, replication genes and capsid genes are provided in trans (in pRep / Cap plasmids), and only the 2ITR of the AAV genome is retained and packaged into the virion, while the required adenoviral genes are provided by adenovirus or another plasmid. Similar modifications can also be made to lentiviral vectors.
[0112] Viral vectors have the ability to enter cells. However, non-viral vectors such as plasmids can be compounded with reagents to facilitate the uptake of viral vectors by target cells. Such reagents include polycationic agents. Alternatively, delivery systems such as liposome-based delivery systems can be used. The carrier used in the present invention is preferably suitable for use in vivo or in vitro, and is preferably suitable for use in humans.
[0113] The vector will preferably comprise one or more regulatory sequences to direct the expression of the nucleic acid sequence in the target cell. The regulatory sequence may comprise a promoter, an enhancer, a transcription termination signal, a polyadenylation sequence, a replication origin, a nucleic acid restriction site, and a homologous recombination site operably connected to the nucleic acid sequence. The vector may also comprise a selective marker, for example to determine the expression of the vector in a growth system (e.g., a bacterial cell) or in a target cell.
[0114] "Operably linked" means that a nucleic acid sequence is functionally related to a sequence to which it is operably linked, such that they are linked in a manner such that they affect the expression or function of each other. For example, a nucleic acid sequence operably linked to a promoter will have an expression pattern affected by the promoter.
[0115] The promoter mediates the expression of the nucleic acid sequence connected thereto. The promoter may be constitutive or inducible. The promoter may direct the universal expression of a gene in cochlear cells, or the specific expression of cochlear cells. In the latter case, the promoter may direct the specific expression of a cell type, such as cochlear supporting cells (SC) (including columnar cells (PC), Deiters cells (DC)). Suitable promoters will be known to those skilled in the art. For example, suitable promoters may be selected from the group consisting of: L7, thy-1, recovery protein, calcium binding protein, human CMV, GAD-67, chicken actin, CAG and CBA, etc. In addition, gene expression targeting specific cells may be achieved using cell-specific promoters.
[0116] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive any polynucleotide sequence operably connected thereto to express at a high level. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr (Epstein-Barr) virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, heme promoter, and creatine kinase promoter. Further, the present invention should not be limited to the application of constitutive promoters. Inducible promoters are also considered to be part of the present invention. The use of an inducible promoter provides a molecular switch that can turn on the expression of a polynucleotide sequence operably connected to the inducible promoter when expression is desired, or turn off expression when expression is desired to be turned off. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
[0117] Many expression vectors can be used to express Ikzf2 protein and Atoh1 protein in mammalian cells (preferably human, more preferably human cochlear supporting cells). The present invention preferably uses adeno-associated virus AAV vector as an expression vector.
[0118] The present invention also provides a host cell for expressing Ikzf2 protein and Atoh1 protein. Preferably, the host cell is a mammalian cell (preferably human, more preferably human cochlear supporting cell), and the expression level of Ikzf2 protein and Atoh1 protein is increased.
[0119] Pharmaceutical preparations and compositions
[0120] The present invention provides a pharmaceutical preparation or composition, which contains (a) the active ingredient combination described in the second aspect of the present invention, or the carrier described in the third aspect of the present invention, or the host cell described in the fourth aspect of the present invention, and (b) a pharmaceutically acceptable carrier or excipient.
[0121] In another preferred embodiment, the pharmaceutical preparation is used to treat hearing loss.
[0122] In another preferred embodiment, the pharmaceutical preparation is used to treat degeneration and / or damage of cochlear outer hair cells.
[0123] The "active ingredient" in the pharmaceutical preparation described in the present invention refers to the vector described in the present invention, such as a viral vector (including an adeno-associated viral vector). The "active ingredient", preparation and / or composition described in the present invention can be used to treat hearing loss. "Safe and effective amount" means: the amount of active ingredient is sufficient to significantly improve the condition or symptoms without causing serious side effects. "Pharmaceutically acceptable carrier or excipient" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the active ingredient of the present invention and with each other without significantly reducing the efficacy of the active ingredient.
[0124] The composition may be a liquid or solid, such as a powder, gel or paste. Preferably, the composition is a liquid, preferably an injectable liquid. Suitable excipients will be known to those skilled in the art.
[0125] In the present invention, the carrier can be administered to the subject by directly to the ear or cochlea. In either mode of administration, preferably, the carrier is provided as an injectable liquid. Preferably, the injectable liquid is provided as a capsule or a syringe.
[0126] In the present invention, the host cells of the present invention can be implanted into the cochlea of a subject for administration. Preferably, the host cells are provided as an injectable liquid.
[0127] Examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0128] The composition may comprise a physiologically acceptable sterile aqueous or anhydrous solution, dispersion, suspension or emulsion, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0129] Treatment
[0130] The present invention provides a method for regenerating cochlear outer hair cells, the method comprising introducing a nucleotide sequence encoding Ikzf2 protein and Atoh1 protein into the cochlea. The method may comprise administering a vector comprising a nucleotide sequence encoding Ikzf2 protein and Atoh1 protein to supporting cells of the cochlea.
[0131] The present invention provides a pharmaceutical preparation or composition for use in a method for treating hearing loss by regenerating cochlear outer hair cells, the pharmaceutical preparation or composition comprising a vector encoding a nucleotide sequence of an Ikzf2 protein and an Atoh1 protein or a host cell containing the vector, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical preparation or composition of the present invention can be administered alone or in combination with other therapeutic drugs (such as formulated in the same pharmaceutical composition).
[0132] The present invention also provides a method for treating hearing loss, the method comprising administering the pharmaceutical preparation or composition of the present invention to a subject. The hearing loss is hearing loss associated with degeneration and / or damage of cochlear outer hair cells. The method comprises directly administering the vector of the present invention comprising the nucleotide sequence encoding the Ikzf2 protein and the Atoh1 protein to the ear (cochlea) of a subject in need. The method also comprises directly implanting the host cell of the present invention into the cochlea of a subject in need.
[0133] As used herein, regenerating cochlear outer hair cells means that cells that did not previously have cochlear outer hair cell capabilities or whose cochlear outer hair cell capabilities have been completely or partially degenerated become cells that possess cochlear outer hair cell characteristics and functions after expressing foreign nucleic acid sequences encoding Ikzf2 protein and Atoh1 protein therein. Such cells may be referred to herein as transformed cells, or "cochlear outer hair cell-like cells (OHC-like cells)", because they contain non-natural nucleic acids therein. Preferably, the transformed cochlear outer hair cells exhibit some or all of the cochlear outer hair cell capabilities of natural cochlear outer hair cells. Preferably, the transformed cells exhibit at least the same or substantially the same hearing capabilities of natural cochlear outer hair cells. Preferably, the transformed cells exhibit higher hearing capabilities than diseased or degenerating natural cochlear outer hair cells. Therefore, the transformed cells will preferably have increased cochlear outer hair cells compared to untreated degenerated or diseased cells from the same source, maintained under the same conditions. The transformed cells can be distinguished from natural cells by the presence of exogenous nucleic acids therein.
[0134] Compared with the prior art, the main advantages of the present invention are:
[0135] (1) The present inventors ectopically co-expressed Ikzf2 protein and Atoh1 protein in cochlear supporting cells to transform cochlear supporting cells into OHC-like cells. The transformed OHC-like cells have similar tissue morphology and gene characteristics as natural OHCs and have the same OHC functions.
[0136] (2) After OHC injury occurs, the method of the present invention can quickly and efficiently generate OHC-like cells.
[0137] (3) The method of the present invention provides a new idea for gene therapy for hearing impairment and hearing loss.
[0138] The present invention will be further described below in conjunction with specific implementation. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0139] Methods and Materials:
[0140] (1) Construction of Rosa26-CAG-LSL-Ikzf2 / + and Prestin-DTR / + site-directed knock-in mouse strains by CRISPR / Cas9
[0141] At the same time, Rosa26-CAG-LSL-Ikzf2 / + site-directed knock-in mice were constructed by simultaneously injecting Rosa26 sgRNA (5'-actccagtctttctagaaga-3', SEQ ID No: 5), donor DNA and Cas9 mRNA into one-cell stage fertilized eggs. The Prestin-P2A-DTR / + (Prestin-DTR / +) site-directed knock-in mouse strain (Prestin (Slc26a5), whose sgRNA is 5'-CGAGGCATAAAGGCCCTGTA-3' (SEQ ID No: 6) was constructed by the same method.
[0142] The correct mice in F0 were screened by junction PCR, and then the potential correct F0 mice were mated with wild-type C57BL / 6 mice to obtain F1 mice. First, the tails of F1 mice were identified by junction PCR to screen out the potential correct mice, and then the mice with random insertions in F1 were excluded by Southern blotting experiments according to the method described in (Li et al., 2018). All mice were bred and raised in SPF-level mouse houses. All operations were carried out according to the guidance of the Institute of Neuroscience and the Center for Excellence in Brain Science and Intelligence of the Chinese Academy of Sciences.
[0143] (2) Sample processing, immunohistochemistry and cell counting
[0144] Adult mice were perfused with 1xPBS and 4% PFA to completely remove blood from the inner ear and perform pre-fixation. The inner ear was then carefully dissected out and placed in a tube containing 4% PFA at 4°C overnight for post-fixation. The next day, the inner ear was washed three times with 1xPBS for 10 minutes each, followed by decalcification with 120mM EDTA for 2 days until the inner ear became soft. The entire cochlear epithelium was then dissected out and subjected to immunohistochemistry.
[0145] The primary antibodies used are shown in the following table:
[0146] Antibody Information Sheet
[0147]
[0148]
[0149] Cochlear tissue was stained with Hoechst33342 (1:1000, 62249, Thermo Scientific) dissolved in PBST to observe the cell nucleus, and the slides were mounted with Prolong gold antifade medium (P36930, Thermo Scientific). Images were taken with Nikon C2, TiE-A1 and NiE-A1 plus confocal microscopes.
[0150] During dissection, each cochlea was divided into three sections and photographed under a 10x objective. The length of the cochlea was then measured by drawing a line between the inner and outer hairs using software, and the cochlea was evenly divided into three sections: basal, middle, and apical. In order to see the death of outer hair cells in the Prestin-DTR / + mouse model, two random positions were photographed in each section under a 60x objective, and the counting results of the two positions were averaged, and inner hair cells were used as a reference because DT does not kill inner hair cells. For Prestin in inner hair cells in Atoh1CreER+; Rosa26-CAG-LSL-Ikzf2 / + mice, and Tdtomato+ / HA+ cells, OHC-like cells, and early nascent hair cell signals in Fgfr3-Atoh1-Ikzf2 and Fgfr3-Atoh1-Ikzf2-DTR mouse models, the entire cochlea was photographed in a 60x mosaic mode for more accurate counting. GraphPad Prism 6.0 was used to make statistical graphs, and the data were analyzed using Student's t test and Mean ± SEM.
[0151] (3) Single-cell sequencing and bioinformatics analysis
[0152] Tdtomato+ cells were used in three mouse models: 1) Prestin-CreER / +; Ai9 / + mice were given Tamoxifen at P20 and P21, and cells were selected at P30 (Fang et al., 2012); 2) Fgfr3-iCreER+; Ai9 / + mice were given Tamoxifen at P30 and P31, and supporting cells (primarily PCs and DCs) were selected at P60, according to previous reports (Liu et al., 2012a; Liu et al., 2012b); 3) Fgfr3-Atoh1-Ikzf2-DTR mice were given Tamoxifen at P30 and P31, DT was given at P36, and cells were selected at P60.
[0153] Tdomato+ cells, 17 wild-type outer hair cells at P30, 16 wild-type supporting cells at P60, and 42 cells in the Fgfr3-Atoh1-Ikzf2-DTR model were hand-picked under a stereo microscope (Fig. 6D), immediately inverted, and cDNA was amplified using the smart-Seq HT kit (Cat#634437, Takara). cDNA (1ng) was quality checked using the TruePrep DNA Library Prep Kit V2 (Cat#TD503, Vazyme) and TruePrep Index Kit V2 (Cat#TD202, Vazyme). Finally, the cDNA library was paired sequenced using the Illumina Novaseq platform, and the sequencing depth of each library was 4G.
[0154] FastQC (v0.11.9) and trimmomatic (v0.39) were used to quality check the raw sequencing data. Approximately 70–80% of the mouse reference genes were covered with high-quality reads using Hisat2 (v2.1.0) with default parameters. The raw data were calculated using HTSeq (v0.10.0). Gene expression levels were estimated using StringTie (v1.3.5) with default parameters. Gene abundance was presented as transcripts per million (TPM). The expression of different genes was analyzed using the R package “DESeq2” (p.adj<0.05, absolute value of (log2 Fold Change)>2). DEGs were enriched for biological analysis (p<0.05, calibrated with bonferroni corrections), and the database was annotated, visualized, and integrated. All the raw data GEO (Gene Expression Omnibus) of single-cell sequencing in the present invention can be obtained using the search code: GSE161156.
[0155] Seurat (R package v3.0) was used to analyze the data of wild-type outer hair cells at E16, P1, and P7 in the literature (Kolla et al., 2020). In order to more accurately compare the transcriptomic data analyzed by 10x and samrt-seq sequencing methods, they were first integrated using the "FindIntegrationAnchors" (k.filter=30) function. Then the component calculation was performed using the "RunPCA" function, and the dimensionality reduction analysis of the top 20 principal components was performed using "RunTSNE" and "RunUMAP". Unsupervised clustering analysis was performed using the "FindClusters" (resolution=0.5) function. In addition, in order to more accurately analyze the progenitor cells of hair cells (E16, E17, and P7) and hair cells (E14) in single-cell sequencing, the criteria set were stricter than the traditional ones. Among them, the expression of Insm1, Myo6 and Atoh1 in wild-type outer hair cells at E16 was greater than 0, and that of Bcl11b, Myo6, Myo7a, and Atoh1 in wild-type outer hair cells at P1 was greater than 0; and that of Prestin (Slc26a5), Myo6, Ocm, and Ikzf2 in wild-type outer hair cells at P7 was greater than 0. Monocle (R package v2.0) was used for trajectory analysis. The preprocessed Seurat data were imported into Monocle using the “importCDS” function. Genes that were significantly changed in outer hair cells at three ages were identified by different expression analyses. The cells were presented along a putative axis using the “orderCells” function in Monocle.
[0156] (4) Auditory brainstem response (ABR)
[0157] The auditory brainstem response of mice was tested according to the previous method (Li et al., 2018). Prestin-DTR / + mice were tested at P42 and P60 (with or without DT treatment at P36) and Fgfr3-Atoh1-Ikzf2-DTR mice at 4kHz, 5.6k Hz, 8k Hz, 11.3k Hz, 16k Hz, 22.6k Hz and 32k Hz. The data were statistically analyzed using Student's t test.
[0158] (5) Tamoxifen and diphtheria toxin
[0159] Tamoxifen (Cat#T5648, Sigma) was dissolved in corn oil (Cat#C8267, sigma) for subsequent experiments. It was injected intraperitoneally at a dose of 3 mg / 40 g (P0, P1) or 9 mg / 40 g (P20, P21 and P30, P31) according to body weight. Diphtheria toxin (Cat#D0564, Sigma) was dissolved in 0.9% NaCl and injected intraperitoneally at a dose of 20 ng / g according to body weight at P36.
[0160] (6) Scanning electron microscopy (SEM)
[0161] SEM experiments were performed according to the previous method (Parker et al., 2016). First, we used forceps to make a hole at the top of the cochlea, then slowly injected 0.9% NaCl (Cat#10019318, Sinopharm Chemical Reagent Co, Ltd) into the round window with a syringe to rinse the cochlea, then injected 2.5% glutaraldehyde (Cat#G5882, Sigma) to pre-fix the cochlea, and then used forceps to expose as much of the organ of Corti as possible for adequate fixation, and finally placed the cochlea in 2.5% glutaraldehyde at 4°C overnight. The next day, the inner ear was rinsed three times with 1xPBS and decalcified with 10% EDTA (Cat#ST066, Beyotime) for 1 day. The cochlea was then removed and postfixed with 1% osmium tetroxide (OsO4, Cat#18451, Tedpella) for 1 hour, washed 6 times with ddH2O, fixed with TCH (thiocarbohydyazide, Cat#88535, Sigma) for 30 minutes, washed 6 times with ddH2O, fixed with 1% osmium tetroxide for 1 hour, washed 6 times with ddH2O, and then dehydrated with different concentrations of ethanol (30%, 50%, 75%, 80%, 95%, Cat#10009259, Sinopharm Chemical Reagent Co, Ltd) at 4 degrees Celsius for 30 minutes each step. Then, the cochlear samples were dehydrated in 100% ethanol 3 times for 30 minutes each time. Next, the sample was critical point dried (model: EM CPD300, Leica). Then the cochlea was pasted on the conductive glue with the front side facing up, and the sample was sprayed with gold (model: Q150T ES, Quorum). Finally, the sample was photographed with a scanning electron microscope (model: GeminiSEM 300, ZEISS).
[0162] Example 1
[0163] After ectopic overexpression of Ikzf2 in inner hair cells, inner hair cells begin to express Prestin
[0164] In wild-type mice, Ikzf2 and Prestin are only expressed in the outer hair cells of the cochlea, and the inner hair cells never express Ikzf2 and Prestin. Rosa26-CAG-LSL-Ikzf2 / + gene-directed mice were constructed to overexpress Ikzf2. Figure 1 A shows the principle of ectopic expression of Ikzf2. When Ikzf2 is expressed, the HA tag fused to Ikzf2 and Tdtomato following it are also expressed, and the cells expressing Ikzf2 emit red fluorescence. After mice were injected with tamoxifen, compared with the control mice ( Figure 1 BB”'), when Ikzf2 is forcibly overexpressed in inner hair cells, prestin is also ectopically expressed in inner hair cells ( Figure 1 CC”'). Quantitative analysis of Prestin-positive inner hair cells revealed that there were more Prestin-positive inner hair cells in Apical turn than in Middle and Basal turn ( Figure 1 D). It was verified that only the experimental group (Figure F) expressed HA / Tdtomato, while the control group (Figure E) did not express it, and all Tdtomato-positive cells expressed HA (Ikzf2), and vice versa.
[0165] Example 2
[0166] Overexpression of Aoh1 and Ikzf2 in PCs and DCs of adult mice simultaneously generated a small number of OHC-like cells
[0167] The effects of different treatments on OHC-like cells were compared. Specifically, three different treatments were performed in adult cochlear supporting cells: overexpression of Atoh1 alone, overexpression of Ikzf2 alone, and overexpression of Atoh1 and Ikzf2 simultaneously. Compared with the control group ( Figure 2 AA”'), overexpression of Atoh1 alone ( Figure 2 BB”') or overexpression of Ikzf2 alone ( Figure 2 CC' and Figure 2 DD”') could not generate new Prestin+ outer hair cells. However, simultaneous overexpression of Atoh1 and Ikzf2 ( Figure 2 EE"' and Figure 2 FF”') can generate a small number of new Prestin+ outer hair cells. Quantitative analysis of OHC-like cells in mice overexpressing both Atoh1 and Ikzf2 (Fgfr3-Atoh1-Ikzf2) was performed ( Figure 2 G) and found that although new cells can be seen throughout the cochlea, the number is small and varies greatly. Summarizing the three different reprogramming treatments, it was found that only by activating Atoh1 and Ikzf2 at the same time can OHC-like cells be generated ( Figure 2 H).
[0168] Example 3
[0169] Specific injury of outer hair cells by genetic and pharmacological approaches
[0170] In order to simulate the human hearing loss model, Prestin-P2A-DTR / + gene knock-in mice were constructed. After diphtheria toxin (DT) was administered to adult (P36) mice, cochlear outer hair cells were specifically killed ( Figure 3 A-A' and Figure 3 B-B'). Statistical analysis showed that more than 90% of the outer hair cells died. However, it is worth noting that the inner hair cells were normal. In addition, after DT treatment, the hearing threshold of the entire cochlea increased significantly ( Figure 3 C). The OHC / IHC ratios of the control and experimental groups were statistically analyzed and it was found that the ratio of the experimental group was significantly lower than that of the control group ( Figure 3 D). The above results show that the hearing loss model was successfully constructed.
[0171] Example 4
[0172] Damage to outer hair cells in situ promotes reprogramming efficiency by overexpressing Atoh1 and Ikzf2 in adult supporting cells
[0173] A hearing-impaired model was established by genetic and pharmacological methods, and specific killing of adult outer hair cells was achieved. Then, Atoh1 was overexpressed in adult supporting cells of hearing-impaired model mice. Figure 4 E), or overexpression of Ikzf2 alone ( Figure 4 F), or overexpression of Atoh1 and Ikzf2 ( Figure 4 GG”’). Figure 4 A and Figure 4 B shows the process of model construction. The experimental results show that only when Atoh1 and Ikzf2 are overexpressed simultaneously can a large number (400-600) of new Prestin+ OHC-like cells be generated. At the same time, the quantitative analysis of the number of OHC-like cells in Fgfr3-Atoh1-Ikzf2-DTR mice ( Figure 4H), Comparison of the number of OHC-like cells in the Fgfr3-Atoh1-Ikzf2-DTR and Fgfr3-Atoh1-Ikzf2 (without destruction of in situ outer hair cells) mouse models. It was found that Fgfr3-Atoh1-Ikzf2-DTR had more OHC-like cells than Fgfr3-Atoh1-Ikzf2. The above results indicate that killing endogenous outer hair cells can significantly increase the efficiency of Atoh1 and Ikzf2 in transdifferentiating supporting cells into new outer hair cells.
[0174] Example 5
[0175] OHC-like cells exhibit irregular ciliary bundles
[0176] Ultra-high scanning electron microscopy was used to conduct a detailed analysis of the auditory epithelium of the cochlea of three different mouse genotypes. The outer hair cells of wild-type mice have 'V' or 'W' shaped cilia on top ( Figure 5 A-A'). The cilia are an ultrastructure that is important for outer hair cells to sense sound. The cilia disappear in the outer hair cell killing model ( Figure 5 B), but reappeared in a model in which adult supporting cells overexpressed Atoh1 and Ikzf2 ( Figure 5 C-C'). This result shows that the newly formed outer hair cells (i.e., OHC-like cells) have ciliary structures.
[0177] Example 6
[0178] OHC-like cells resemble wild-type outer hair cells at P1
[0179] Wild-type cochlear supporting cells and outer hair cells were genetically labeled red, and then cochlear tissue was digested and manually sorted for single-cell transcriptome analysis ( Figure 6 A). At the same time, a similar approach was used to select supporting cells that overexpress Atoh1 and Ikzf2 for single-cell transcriptome analysis ( Figure 6 A). Myo7a and Prestin immunohistochemistry ( Figure 6 BC"'), it was found that the supporting cells expressing Atoh1 and Ikzf2 ultimately had three cell fates: 1) not transformed into hair cells (triangle); 2) transformed into very immature hair cells (asterisk); 3) transformed into newborn Prestin+ OHC-like cells (the type of most concern in this invention) (arrow). UMAP analysis showed that the newly generated cells were closer to adult outer hair cells, but did not completely overlap ( Figure 6 D and Figure 6E). For further analysis, by comparing the transcriptome data of hair cells at different stages of the study, which was recently published in Nature Communications in 2020, it was found that Prestin+ newborn outer hair cells were most similar to wild-type outer hair cells on the first day after birth (P1) ( Figure 6 F and Figure 6 G).
[0180] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application. Sequence Listing <110> Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences <120> Regeneration of cochlear outer hair cells by ectopic combined overexpression of Atoh1 and Ikzf2 and its application <130> P2020-2480 <160> 8 <170> PatentIn version 3.5 <210> 1 <211> 526 <212> PRT <213> Homo sapiens <400> 1 Met Glu Thr Glu Ala Ile Asp Gly Tyr Ile Thr Cys Asp Asn Glu Leu 1 5 10 15 Ser Pro Glu Arg Glu His Ser Asn Met Ala Ile Asp Leu Thr Ser Ser 20 25 30 Thr Pro Asn Gly Gln His Ala Ser Pro Ser His Met Thr Ser Thr Asn 35 40 45 Ser Val Lys Leu Glu Met Gln Ser Asp Glu Glu Cys Asp Arg Lys Pro 50 55 60 Leu Ser Arg Glu Asp Glu Ile Arg Gly His Asp Glu Gly Ser Ser Leu 65 70 75 80 Glu Glu Pro Leu Ile Glu Ser Ser Glu Val Ala Asp Asn Arg Lys Val 85 90 95 Gln Glu Leu Gln Gly Glu Gly Gly Ile Arg Leu Pro Asn Gly Lys Leu 100 105 110 Lys Cys Asp Val Cys Gly Met Val Cys Ile Gly Pro Asn Val Leu Met 115 120 125 Val His Lys Arg Ser His Thr Gly Glu Arg Pro Phe His Cys Asn Gln 130 135 140 Cys Gly Ala Ser Phe Thr Gln Lys Gly Asn Leu Leu Arg His Ile Lys 145 150 155 160 Leu His Ser Gly Glu Lys Pro Phe Lys Cys Pro Phe Cys Ser Tyr Ala 165 170 175 Cys Arg Arg Arg Asp Ala Leu Thr Gly His Leu Arg Thr His Ser Val 180 185 190 Gly Lys Pro His Lys Cys Asn Tyr Cys Gly Arg Ser Tyr Lys Gln Arg 195 200 205 Ser Ser Leu Glu Glu His Lys Glu Arg Cys His Asn Tyr Leu Gln Asn 210 215 220 Val Ser Met Glu Ala Ala Gly Gln Val Met Ser His His Val Pro Pro 225 230 235 240 Met Glu Asp Cys Lys Glu Gln Glu Pro Ile Met Asp Asn Asn Ile Ser 245 250 255 Leu Val Pro Phe Glu Arg Pro Ala Val Ile Glu Lys Leu Thr Gly Asn 260 265 270 Met Gly Lys Arg Lys Ser Ser Thr Pro Gln Lys Phe Val Gly Glu Lys 275 280 285 Leu Met Arg Phe Ser Tyr Pro Asp Ile His Phe Asp Met Asn Leu Thr 290 295 300 Tyr Glu Lys Glu Ala Glu Leu Met Gln Ser His Met Met Asp Gln Ala 305 310 315 320 Ile Asn Asn Ala Ile Thr Tyr Leu Gly Ala Glu Ala Leu His Pro Leu 325 330 335 Met Gln His Pro Pro Ser Thr Ile Ala Glu Val Ala Pro Val Ile Ser 340 345 350 Ser Ala Tyr Ser Gln Val Tyr His Pro Asn Arg Ile Glu Arg Pro Ile 355 360 365 Ser Arg Glu Thr Ala Asp Ser His Glu Asn Asn Met Asp Gly Pro Ile 370 375 380 Ser Leu Ile Arg Pro Lys Ser Arg Pro Gln Glu Arg Glu Ala Ser Pro 385 390 395 400 Ser Asn Ser Cys Leu Asp Ser Thr Asp Ser Glu Ser Ser His Asp Asp 405 410 415 His Gln Ser Tyr Gln Gly His Pro Ala Leu Asn Pro Lys Arg Lys Gln 420 425 430 Ser Pro Ala Tyr Met Lys Glu Asp Val Lys Ala Leu Asp Thr Thr Lys 435 440 445 Ala Pro Lys Gly Ser Leu Lys Asp Ile Tyr Lys Val Phe Asn Gly Glu 450 455 460 Gly Glu Gln Ile Arg Ala Phe Lys Cys Glu His Cys Arg Val Leu Phe 465 470 475 480 Leu Asp His Val Met Tyr Thr Ile His Met Gly Cys His Gly Tyr Arg 485 490 495 Asp Pro Leu Glu Cys Asn Ile Cys Gly Tyr Arg Ser Gln Asp Arg Tyr 500 505 510 Glu Phe Ser Ser His Ile Val Arg Gly Glu His Thr Phe His 515 520 525 <210> 2 <211> 354 <212> PRT <213> Homo sapiens <400> 2 Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu 1 5 10 15 Gly Asp His His Arg Gln Pro Gln Pro His His Leu Pro Gln Pro Pro 20 25 30 Pro Pro Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Glu His Pro Val 35 40 45 Tyr Pro Pro Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp 50 55 60 Leu Ala Pro Thr Leu Gln Gly Ile Cys Thr Ala Arg Ala Ala Gln Tyr 65 70 75 80 Leu Leu His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg 85 90 95 Asp Glu Val Asp Gly Arg Gly Glu Leu Val Arg Arg Ser Ser Gly Gly 100 105 110 Ala Ser Ser Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu 115 120 125 Cys Lys Leu Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg 130 135 140 Gln Arg Ala Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg 145 150 155 160 Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn 165 170 175 His Ala Phe Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp 180 185 190 Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile 195 200 205 Asn Ala Leu Ser Glu Leu Leu Gln Thr Pro Ser Gly Gly Glu Gln Pro 210 215 220 Pro Pro Pro Pro Ala Ser Cys Lys Ser Asp His His His Leu Arg Thr 225 230 235 240 Ala Ala Ser Tyr Glu Gly Gly Ala Gly Asn Ala Thr Ala Ala Gly Ala 245 250 255 Gln Gln Ala Ser Gly Gly Ser Gln Arg Pro Thr Pro Pro Gly Ser Cys 260 265 270 Arg Thr Arg Phe Ser Ala Pro Ala Ser Ala Gly Gly Tyr Ser Val Gln 275 280 285 Leu Asp Ala Leu His Phe Ser Thr Phe Glu Asp Ser Ala Leu Thr Ala 290 295 300 Met Met Ala Gln Lys Asn Leu Ser Pro Ser Leu Pro Gly Ser Ile Leu 305 310 315 320 Gln Pro Val Gln Glu Glu Asn Ser Lys Thr Ser Pro Arg Ser His Arg 325 330 335 Ser Asp Gly Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu 340 345 350 Ala Ser <210> 3 <211> 1581 <212> DNA <213> Homo sapiens <400> 3 atggaaacag aggctattga tggctatata acgtgtgaca atgagctttc acccgaaagg 60 gagcactcca atatggcaat tgacctcacc tcaagcacac ccaatggaca gcatgcctca 120 ccaagtcaca tgacaagcac aaattcagta aagctagaaa tgcagagtga tgaagagtgt 180 gacaggaaac ccctgagccg tgaagatgag atcaggggcc atgatgaggg tagcagccta 240 gaagaacccc taattgagag cagcgaggtg gctgacaaca ggaaagtcca ggagcttcaa 300 ggcgagggag gaatccggct tccgaatggt aaactgaaat gtgacgtctg tggcatggtt 360 tgcattgggc ccaatgtgct tatggtacat aaaaggagtc acactggtga acgccccttc 420 cactgtaacc agtgtggagc ttcttttact cagaagggca accttctgag acacataaag 480 ttacactctg gagagaagcc gttcaaatgt cctttctgta gctacgcctg tagagaagg 540 gacgccctca caggacacct caggacccat tctgtgggta aacctcacaa gtgcaactac 600 tgtggacgaa gctacaagca gcgcagttca ctggaggac acaaggaacg ctgccacaac 660 tatctccaga atgtcagcat ggaggctgct gggcaggtca tgagtcacca tgtacctcct 720 atggagaatt gtaaggaaca agagcctatt atggacaaca atatttctct ggtgcctttt 780 gagagacctg ctgtcataga gaagctcacg gggaatatgg gaaaacgtaa aagctccact 840 ccacaaaagt ttgtggggga aaagctcatg cgattcagct acccagatat tcactttgat 900 atgaacttaa catatgagaa ggaggctgag ctgatgcagt ctcatatgat ggaccaagcc 960 atcaacaatg caatcaccta ccttggagct gaggcccttc accctctgat gcagcacccg 1020 ccaagcacaa tcgctgaagt ggccccagtt ataagctcag cttattctca ggtctatcat 1080 ccaaatagga tagaaagacc cattagcagg gaaactgctg atagtcatga aaacaacatg 1140 gatggcccca tctctctcat cagaccaaag agtcgacccc aggaagaga ggcctctccc 1200 agcaatagct gcctggattc cactgactca gaagcagcc atgatgacca ccagtcctac 1260 cagcacacc ctgccttaaa tcccagagg aaaaaagcc cagcacat 1320 gtcaaagctt tggatactac aaggctcct aagggctctc tgaggacat ctacaagctc 1380 ttcaatggag aaggagaaca gattaggggcc ttcaagtg agcactgccg agtccttttc 1440 ctagaccatg tcatgtacac cattcacatg gttgccatg gctaccggga cccactggaa 1500 tgcacatct gtggctacag aagccaggac cgttatgagt ttcatcaca cattgttcga 1560 ggggagcaca cattccacta g 1581 <210> 4 <211> 1065 <212> DNA <213> Humans (Homo sapiens) <400> 4 atgtcccgcc tgctgcatgc agaagagtgg gctgaagtga aggagttggg agaccaccat 60 cgccagcccc agccgcatca tctcccgcaa ccgccgccgc cgccgcagcc acctgccact 120 ttgcaggcga gagagcatcc cgtctacccg cctgagctgt ccctcctgga cagcaccgac 180 ccacgcgcct ggctggctcc cactttgcag ggcatctgca cggcacgcgc cgcccagtat 240 ttgctacatt ccccggagct gggtgcctca gaggccgctg cgccccgggga cgaggtggac 300 ggccgggggg agctggtaag gaggagcagc ggcggtgcca gcagcagcaa gagccccggg 360 ccggtgaaag tgcgggaaca gctgtgcaag ctgaaaggcg gggtggtggt agacgagctg 420 ggctgcagcc gccaacgggc cccttccagc aaacaggtga atggggtgca gaagcagaga 480 cggctagcag ccaacgccag ggagcggcgc aggatgcatg ggctgaacca cgccttcgac 540 cagctgcgca atgttatccc gtcgttcaac aacgacaaga agctgtccaa attgagacc ctgcagatgg cccaaatcta catcaacgcc ttgtccgagc tgctacaaac gcccagcgga ggggaacagc caccgccgcc tccagcctcc tgcaaaagcg accaccacca ccttcgcacc gcggcctcct atgaaggggg cgcgggcaac gcgaccgcag ctggggctca gcaggcttcc 780 ggagggagcc agcggccgac cccgcccggg agttgccgga ctcgcttctc agccccagct 840 tctgcgggag ggtactcggt gcagctggac gctctgcact tctcgacttt cgaggacagc 900 gccctgacag cgatgatggc gcaaaagaat ttgtctcctt ctctccccgg gagcatcttg 960 cagccagtgc aggaggaaaa cagcaaaact tcgcctcggt cccacagaag cgacggggaa 1020 ttttcccccc attcccatta cagtgactcg gatgaggcaa gttag 1065 <210> 5 <211> 526 <212> PRT <213> Mouse (Mus musculus) <400> 5 Met Glu Thr Asp Ala Ile Asp Gly Tyr Ile Thr Cys Asp Asn Glu Leu 1 5 10 15 Ser Pro Glu Gly Glu His Ala Asn Met Ala Ile Asp Leu Thr Ser Ser 20 25 30 Thr Pro Asn Gly Gln His Ala Ser Pro Ser His Met Thr Ser Thr Asn 35 40 45 Ser Val Lys Leu Glu Met Gln Ser Asp Glu Glu Cys Asp Arg Gln Pro 50 55 60 Leu Ser Arg Glu Asp Glu Ile Arg Gly His Asp Glu Gly Ser Ser Leu 65 70 75 80 Glu Glu Pro Leu Ile Glu Ser Ser Glu Val Ala Asp Asn Arg Lys Val 85 90 95 Gln Asp Leu Gln Gly Glu Gly Gly Ile Arg Leu Pro Asn Gly Lys Leu 100 105 110 Lys Cys Asp Val Cys Gly Met Val Cys Ile Gly Pro Asn Val Leu Met 115 120 125 Val His Lys Arg Ser His Thr Gly Glu Arg Pro Phe His Cys Asn Gln 130 135 140 Cys Gly Ala Ser Phe Thr Gln Lys Gly Asn Leu Leu Arg His Ile Lys 145 150 155 160 Leu His Ser Gly Glu Lys Pro Phe Lys Cys Pro Phe Cys Ser Tyr Ala 165 170 175 Cys Arg Arg Arg Asp Ala Leu Thr Gly His Leu Arg Thr His Ser Val 180 185 190 Gly Lys Pro His Lys Cys Asn Tyr Cys Gly Arg Ser Tyr Lys Gln Arg 195 200 205 Ser Ser Leu Glu Glu His Lys Glu Arg Cys His Asn Tyr Leu Gln Asn 210 215 220 Val Ser Met Glu Ala Ala Gly Gln Val Met Ser His His Val Pro Pro 225 230 235 240 Met Glu Asp Cys Lys Glu Gln Glu Pro Ile Met Asp Asn Asn Ile Ser 245 250 255 Leu Val Pro Phe Glu Arg Pro Ala Val Ile Glu Lys Leu Thr Ala Asn 260 265 270 Met Gly Lys Arg Lys Ser Ser Thr Pro Gln Lys Phe Val Gly Glu Lys 275 280 285 Leu Met Arg Phe Ser Tyr Pro Asp Ile His Phe Asp Met Asn Leu Thr 290 295 300 Tyr Glu Lys Glu Ala Glu Leu Met Gln Ser His Met Met Asp Gln Ala 305 310 315 320 Ile Asn Asn Ala Ile Thr Tyr Leu Gly Ala Glu Ala Leu His Pro Leu 325 330 335 Met Gln His Ala Pro Ser Thr Ile Ala Glu Val Ala Pro Val Ile Ser 340 345 350 Ser Ala Tyr Ser Gln Val Tyr His Pro Asn Arg Ile Glu Arg Pro Ile 355 360 365 Ser Arg Glu Thr Ser Asp Ser His Glu Asn Asn Met Asp Gly Pro Ile 370 375 380 Ser Leu Ile Arg Pro Lys Ser Arg Pro Gln Glu Arg Glu Ala Ser Pro 385 390 395 400 Ser Asn Ser Cys Leu Asp Ser Thr Asp Ser Glu Ser Ser His Asp Asp 405 410 415 Arg Gln Ser Tyr Gln Gly Asn Pro Ala Leu Asn Pro Lys Arg Lys Gln 420 425 430 Ser Pro Ala Tyr Met Lys Glu Asp Val Lys Ala Leu Asp Ala Thr Lys 435 440 445 Ala Pro Lys Gly Ser Leu Lys Asp Ile Tyr Lys Val Phe Asn Gly Glu 450 455 460 Gly Glu Gln Ile Arg Ala Phe Lys Cys Glu His Cys Arg Val Leu Phe 465 470 475 480 Leu Asp His Val Met Tyr Thr Ile His Met Gly Cys His Gly Tyr Arg 485 490 495 Asp Pro Leu Glu Cys Asn Ile Cys Gly Tyr Arg Ser Gln Asp Arg Tyr 500 505 510 Glu Phe Ser Ser His Ile Val Arg Gly Glu His Thr Phe His 515 520 525 <210> 6 <211> 351 <212> PRT <213> Mouse (Mus musculus) <400> 6 Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu 1 5 10 15 Gly Asp His His Arg His Pro Gln Pro His His Val Pro Pro Leu Thr 20 25 30 Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Asp Leu Pro Val Tyr Pro 35 40 45 Ala Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp Leu Thr 50 55 60 Pro Thr Leu Gln Gly Leu Cys Thr Ala Arg Ala Ala Gln Tyr Leu Leu 65 70 75 80 His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg Asp Glu 85 90 95 Ala Asp Ser Gln Gly Glu Leu Val Arg Arg Ser Gly Cys Gly Gly Leu 100 105 110 Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu Cys Lys Leu 115 120 125 Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg Gln Arg Ala 130 135 140 Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg Arg Leu Ala 145 150 155 160 Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn His Ala Phe 165 170 175 Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp Lys Lys Leu 180 185 190 Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile Asn Ala Leu 195 200 205 Ser Glu Leu Leu Gln Thr Pro Asn Val Gly Glu Gln Pro Pro Pro Pro 210 215 220 Thr Ala Ser Cys Lys Asn Asp His His His Leu Arg Thr Ala Ser Ser 225 230 235 240 Tyr Glu Gly Gly Ala Gly Ala Ser Ala Val Ala Gly Ala Gln Pro Ala 245 250 255 Pro Gly Gly Gly Pro Arg Pro Thr Pro Pro Gly Pro Cys Arg Thr Arg 260 265 270 Phe Ser Gly Pro Ala Ser Ser Gly Gly Tyr Ser Val Gln Leu Asp Ala 275 280 285 Leu His Phe Pro Ala Phe Glu Asp Arg Ala Leu Thr Ala Met Met Ala 290 295 300 Gln Lys Asp Leu Ser Pro Ser Leu Pro Gly Gly Ile Leu Gln Pro Val 305 310 315 320 Gln Glu Asp Asn Ser Lys Thr Ser Pro Arg Ser His Arg Ser Asp Gly 325 330 335 Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu Ala Ser 340 345 350 <210> 7 <211> 1581 <212> DNA <213> Mouse (Mus musculus) <400> 7 atggaaacag acgcaattga tggctatata acatgtgaca atgagctttc acccgaaggg 60 gaacacgcca atatggccat tgacctcacc tcaagcacac ccaatggaca gcacgcctcg 120 ccaagtcaca tgacaagcac aaattctgta aagctggaaa tgcagagtga tgaagagtgt 180 gacaggcagc ccctgagccg tgaggatgag atcaggggcc acgatgaggg gagcagccta 240 gaagaacccc taattgagag cagcgaggtg gccgacaaca ggaaagtcca ggaccttcaa 300 ggcgagggag gaatccggct tccgaatggt aaactgaaat gtgacgtctg tggcatggtt 360 tgcattgggc ccaatgtgct tatggtacat aaaaggagtc acactggtga gcggcccttc 420 cactgtaacc agtgcggagc ttcttttacc cagaagggca accttctgag acacataaag 480 ttacactctg gagagaagcc cttcaaatgt cctttctgta gctatgcttg tagaagaagg 540 gacgctctca caggacacct caggacccat tctgtgggta aacctcacaa gtgtaactac 600 tgtggccgaa gctacaagca gcgcagctca ctggaggaac aaggaacg ctgtcacaac 660 tatctccaga atgtcagcat ggaggctgcc gggcaggtca tgagtcacca tgtaccgcct 720 atggagatt gtaggaaca agagcctatc atggacaaca atatttctct ggtgcctttt 780 gagagacctg ctgtcataga gaagctcacg gcaataatgg gaagcgcaa aagctccact 840 cctcagaagt ttgtgggg aaagcttatg cgattcagct acccagat tcattttgat 900 atgaacttaa catatgagaa ggaggctgag ctgatgcagt ctcatatgat ggaccaagcc 960 atcacaatg caatcaccta ccttggagct gaggccctc accctgat gcagcatgca 1020 ccaagcacaa tcgctgaggt ggccccagtt ataagctcag cttattctca ggtctatcat 1080 ccaaacagga tagaagacc cattagcagg gaaacatctg atagtcacga aaaaaacaatg 1140 gatggcccca tctctctcat cagaccaaag agtcgacccc aggaagaga ggcctcgccc 1200 agcaatagct gcctcgattc tactgactca gaagtagcc atgatgaccg ccagtcctac 1260 caggaaacc ctgccttaaa tcccagagg aaaaaagcc cagcttacat gaggaggat 1320 gtcaaggctt tggatgctac caaggccccc aagggctctc tgaaggacat ctataaggtt 1380 ttcaatggag aaggagaaca gataagggcc ttcaagtgtg agcactgccg agtccttttt 1440 ctagaccatg tcatgtacac cattcacatg ggttgccatg gctaccggga cccactggaa 1500 tgcaacatct gtggctacag aagccaggac cgctacgaat tttcatcaca cattgttcga 1560 ggggagcaca cattccacta g 1581 <210> 8 <211> 1056 <212> DNA <213> Mouse (Mus musculus) <400> 8 atgtcccgcc tgctgcatgc agaagagtgg gctgaggtaa aagagttggg ggaccaccat 60 cgccatcccc agccgcacca cgtcccgccg ctgacgccac agccacctgc taccctgcag 120 gcgagagacc ttcccgtcta cccggcagaa ctgtccctcc tggatagcac cgacccacgc 180 gcctggctga ctcccacttt gcagggcctc tgcacggcac gcgccgccca gtatctgctg 240 cattctcccg agctgggtgc ctccgaggcc gcggcgcccc gggacgaggc tgacagccag 300 ggtgagctgg taaggagaag cggctgtggc ggcctcagca agagccccgg gcccgtcaaa 360 gtacgggaac agctgtgcaa gctgaagggt ggggttgtag tggacgagct tggctgcagc 420 cgccagcgag ccccttccag caaacaggtg aatggggtac agaagcaaag gaggctggca 480 gcaaacgcaa gggaacggcg caggatgcac gggctgaacc acgccttcga ccagctgcgc 540 aacgttatcc cgtccttcaa caacgacaag aagctgtcca aatatgagac cctacagatg 600 gcccagatct acatcaacgc tctgtcggag ttgctgcaga ctcccaatgt cggagagcaa 660 ccgccgccgc ccacagcttc ctgcaaaaat gaccaccatc accttcgcac cgcctcctcc 720 tatgaaggag gtgcgggcgc ctctgcggta gctggggctc agccagcccc gggagggggc 780 ccgagaccta ccccgcccgg gccttgccgg actcgcttct caggcccagc ttcctctggg 840 ggttactcgg tgcagctgga cgctttgcac ttcccagcct tcgaggacag ggccctaaca 900 gcgatgatgg cacagaagga cctgtcgcct tcgctgcccg ggggcatcct gcagcctgta 960 caggaggaca acagcaaaac atctcccaga tcccacagaa gtgacggaga gttttccccc 1020 cactctcatt acagtgactc tgatgaggcc agttag 1056
Claims
1. Use of an active ingredient combination, It is characterized in that For preparing a preparation or a drug, the preparation or the drug is used for treating hearing loss, the hearing loss is hearing loss associated with cochlear outer hair cell (OHC) degeneration and / or damage, and the preparation or the drug treats hearing loss by regenerating cochlear outer hair cells; Wherein, the active ingredient combination is: (a) Ikzf2 protein, its coding sequence, or a combination thereof; and (b) Atohl protein, its coding sequence, or a combination thereof.
2. The use according to claim 1, It is characterized in that The amino acid sequence of the Ikzf2 protein is shown in SEQ ID NO.:
1.
3. The use according to claim 1, It is characterized in that The amino acid sequence of the Atoh1 protein is shown in SEQ ID NO.:
2.
4. Use of an expression vector, or a host cell comprising the expression vector, in the preparation of a medicament for treating hearing loss associated with cochlear outer hair cell (OHC) degeneration and / or damage; The expression vector comprises: (Z1) a first expression vector, which contains a first expression cassette for expressing the Ikzf2 protein; (Z1) a second expression vector, wherein the second expression vector contains a second expression cassette for expressing the Atoh1 protein; Wherein, the first expression vector and the second expression vector are the same vector or different vectors.
5. The use according to claim 4, It is characterized in that The expression vector is selected from the following group: a lentiviral vector, an adenoviral vector, an adeno-associated viral vector (AAV), or a combination thereof.
6. The use according to claim 4, It is characterized in that The expression vector is an adeno-associated virus vector.
7. The use according to claim 6, It is characterized in that The adeno-associated virus vector is AAV7m8, AAV-anc80, or AAV-ie.
8. The use according to claim 4, It is characterized in that The host cell is a cochlear supporting cell (SC).
9. The use according to claim 4, It is characterized in that The host cell is selected from the group consisting of mast cells (PC), Deiters cells (DC), or a combination thereof.
10. The use according to claim 4, It is characterized in that The host cell is a columnar cell (PC).
Citation Information
Patent Citations
AAV1 vectors and uses thereof for treatment of OTIC indications
WO2020077295A1
